Még nem toboroz
Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.
NCT07717450· 3. fázis· UNICANCER· Forrás
Toboroz
Impact of Endotest on Patients' Quality of Life: a Cohort Study
NCT07560852· ZIWIG· Forrás
Contact: Horace ROMAN, Physician
Toboroz
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( RAINFOL-03 )
2024-519818-31-01· 3. fázis· Genmab A/S· Forrás
Még nem toboroz
ActiTENS Mini (Transcutaneous Electrical Stimulation) in Women With Chronic Pain From Pelvic Endometriosis
NCT07317037· Assistance Publique - Hôpitaux de Paris· Forrás
Contact: ROMAN HORACE
Toboroz
Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management
NCT07371585· 2. fázis· SOLTI Breast Cancer Research Group· Forrás
Toboroz
Pancreatic cancer first-line NALIRIFOX optimization with 5-FU maintenance and role of antibiotics and microbiota exploration in second-line treatment – A non-comparative, randomized phase II PANORAMIX GERCOR G-116 PRODIGE 105 study
2024-517766-41-00· 2. fázis· Association Gercor· Forrás
Még nem toboroz
Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer
NCT07150403· 2. fázis· Federation Francophone de Cancerologie Digestive· Forrás
Toboroz
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
NCT07166094· 3. fázis· Genmab· Forrás
Fut, nem toboroz
Evaluation of the Efficacy of an Innovative Digital Therapeutic Medical Device, Lyv Endo, for the Management of Patients With Endometriosis
NCT07175857· Lyv Healthcare· Forrás
Toboroz
PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatellite unstable or mismatch repair-deficient locally advanced rectal cancer patients: a randomized phase II trial
2024-510772-20-00· 2. fázis· Centre Hospitalier Universitaire De Dijon· Forrás
Toboroz
Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.
NCT06450314· 2. fázis· UNICANCER· Forrás
Toboroz
FLUOCOL-1 : Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage
NCT05168839· 4. fázis· Centre Hospitalier Regional Universitaire· Forrás
Fut, nem toboroz
Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizumab) and
immunotherapy ( Pembrolizumab)
NCT04262687· 2. fázis· Fondation Franc.Cancerologie Digestive· Forrás
Toboroz
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT06393374· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Randomised Clinical Investigation to Assess Efficacy of Low Volume Transanal Irrigation by Qufora® IrriSedo MiniGo Versus Conservative Treatment for Low Anterior Resection Syndrome Patients
NCT06923150· Qufora A/S· Forrás
Contact: Quentin DENOST (principal investigator)
Toboroz
Evaluation of the Medical Benefit of Spa Therapy on Fibrosis After Radiotherapy for Breast Cancer or UADT (Upper Aerodigestive Tract) Cancer
NCT05874492· Association Francaise pour la Recherche Thermale· Forrás
Contact: Christophe Debelleix
Toboroz
DESTINY Breast Respond HER2-(Ultra)Low Europe
NCT05945732· Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company· Forrás
Fut, nem toboroz
Evaluation of the Efficacy of HIFU Treatment on Rectal Endometriosis Symptoms.
NCT05755958· EDAP TMS S.A.· Forrás
Fut, nem toboroz
Trastuzumab deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab as First-line Treatment in HER2-positive, Metastatic Breast Cancer
NCT04784714· 3. fázis· AstraZeneca AB· Forrás
Toboroz
Cohort of the Franco-European Multidisciplinary Institute of Endometriosis
NCT07243587· Clinique Tivoli Ducos· Forrás
Contact: Horace ROMAN
Fut, nem toboroz
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT04711252· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
NCT04595565· 3. fázis· GBG Forschungs GmbH· Forrás
Fut, nem toboroz
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
NCT04258137· Institut Bergonié· Forrás
Toboroz
Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer
NCT03875781· 3. fázis· Assistance Publique - Hôpitaux de Paris· Forrás
Fut, nem toboroz
Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases
NCT03143322· UNICANCER· Forrás
Fut, nem toboroz
International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer
NCT03386734· Centre Hospitalier Universitaire de Besancon· Forrás
Lezárult
IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting
NCT02967289· 3. fázis· UNICANCER· Forrás
Lezárult
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection
NCT03079011· 3. fázis· UNICANCER· Forrás
Toboroz
UroCCR Database: French Research Network for Kidney Cancer -UroCCR
NCT03293563· University Hospital, Bordeaux· Forrás
Contact: Clément MICHIELS, Dr